All In Biotech

Drug Trial Radar · NCT06081530

A Study in Healthy Men to Test How Well Different Doses of BI 3802876 Are Tolerated

Single-blind, Randomised, Placebo-Controlled Trial on the Safety, Tolerability, and Pharmacokinetics of Single Rising Doses and Multiple Doses of Intravenous BI 3802876 in Healthy Subjects

Last checked: Nov 20, 2026Latest source record: Apr 9, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

59

Actual

Start

Oct 27, 2023

Primary completion

Mar 20, 2025

Study completion Mar 20, 2025

Sponsor

Lead sponsor
Boehringer IngelheimBoehringer Ingelheim
Sponsor type
Industry
First posted
Oct 13, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The main objective of this trial is to investigate the safety, tolerability, and pharmacokinetics of BI 3802876 when administered in different doses in healthy male volunteers. The primary objective is to descriptively assess the frequency of drug-related adverse events (AEs) in subjects treated with BI 3802876, as compared to placebo. The secondary objective is to descriptively assess pharmacokinetic parameters.

Conditions

  • Healthy

Interventions

  • BI 3802876Drug

    BI 3802876

  • Placebo matching BI 3802876Drug

    Placebo matching BI 3802876

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part A and Part B: Occurrences of any drug-related AEs between first drug administration (BI 3802876 or placebo) and end of the residual effect period (REP)Time frame: up to Day 35 for Part A and up to Day 117 for Part B

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • SGS Life Science Services - Clinical Research

    Edegem, Belgium

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.